Education
About Us
Working with TipRanks
Follow Us
Peptidream Inc. (JP:4587)
:4587
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
35.47Last Year’s EPS
144.8Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 13, 2025
|% Change Since: -8.99%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Positive
The earnings call presented a largely positive outlook for the company with strong financial performance and promising pipeline developments, despite some challenges in specific segments and uncertainties in deal closures.Company Guidance
During the Q2 2024 earnings call for PeptiDream (4587.T), executive Patrick Reed provided detailed guidance for the second half of 2024 and touched upon early 2025 projections. The company reported a first-half revenue of approximately JPY 36 billion, with JPY 28.5 billion from PeptiDream and JPY 7.6 billion from its radiopharmaceutical business, PDRadiopharma. This surpasses their initial annual revenue forecast of JPY 35 billion, revised to JPY 45 billion following a collaboration with Novartis. Core operating profit and net income exceeded 100% of their goals, reaching JPY 24 billion and JPY 18 billion, respectively. Reed highlighted potential for upward revisions in earnings, driven by additional revenue sources and ongoing negotiations with pharmaceutical partners. The company forecasts second-half milestones and R&D funding between JPY 1.2 billion and JPY 2.5 billion, and anticipates total revenue for fiscal 2024 to be between JPY 15.4 billion and JPY 16.2 billion for PDRadiopharma. The call also emphasized strategic expansions, such as the Novartis collaboration and potential new partnerships, aiming to sustain the company's financial momentum into 2025.Strong First Half Financial Performance
Revenue of JPY 36 billion, which exceeded the initial forecast. Core operating profit reached JPY 24 billion and net income was JPY 18 billion.
Successful Novartis Collaboration and Expansion
The Novartis collaboration expanded and contributed significantly to revenues. Multiple programs are progressing towards clinical entry, with a new component of peptide drug conjugate programs added.
Positive Currency Exchange and Cash Position
Achieved a favorable currency exchange rate with USD 157-158 per JPY and holding over JPY 50 billion in cash as of the end of July.
Promising Pipeline Developments
Progress in the radiopharmaceutical pipeline with several programs moving towards clinical stages. Notable progress in non-radiopharmaceuticals including macrocyclic peptides and oral peptide therapeutics.
Strategic Partnerships and New Management
Strategic partnerships like the acquisition of Amolyt Pharma by AstraZeneca enhance program development. New management in PDRadiopharma to drive growth.
JP:4587 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
JP:4587 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2025 | ¥1846.50 | ¥1850.50 | +0.22% |
Feb 13, 2025 | ¥1932.50 | ¥1989.50 | +2.95% |
Nov 13, 2024 | ¥2827.50 | ¥2748.50 | -2.79% |
Aug 08, 2024 | ¥2413.50 | ¥2454.00 | +1.68% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Peptidream Inc. (JP:4587) report earnings?
Peptidream Inc. (JP:4587) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is Peptidream Inc. (JP:4587) earnings time?
Peptidream Inc. (JP:4587) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Peptidream Inc. stock?
The P/E ratio of Peptidream is N/A.
What is JP:4587 EPS forecast?
JP:4587 EPS forecast for the fiscal quarter 2025 (Q2) is 35.47.